03.01.05
Enzymotec recently released the results of a new human clinical trial that if believes further supports the heart-related benefits of carDiabeat. The study was conducted by Professor Peter Jones at the Mary Emily Clinical Research Unit at McGill University, Canada, over a year-and-a-half period. In this particular trial, the diets of healthy, moderately overweight volunteers with elevated serum lipid levels were supplemented with carDiabeat or commercially available supplements. The objectives of the trial were tested using a randomized, single blind, cross over clinical intervention. Biomarkers in the plasma, such as total cholesterol, LDL cholesterol, HDL cholesterol and total triglycerides levels were monitored. Initial results revealed that carDiabeat had better results on the body’s total lipid profile in comparison to other supplements. More specifically, the study showed that carDiabeat can simultaneously decrease the main risk factors associated with cardiovascular disease.